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Abstract 
α-synuclein (α-syn) is a 140 residue protein that plays a central role in Parkinson’s disease (PD) and 
other neurological disorders. The precise function and pathological properties of α-syn remain 
however poorly understood. While α-syn is considered to be a flexible and disordered protein under 
native conditions, its ability to adopt a variety of conformational ensembles depending on the 
environment is considered to be related to its pathology. Raman optical activity (ROA) is a chiroptical 
spectroscopic technique that is uniquely sensitive to the secondary structure of proteins in solution 
and was used here for the first time to study the different conformational ensembles of α-syn. In this 
paper, the Raman and ROA spectral characteristics of these different conformations of α-syn are 
investigated. We show that Raman and ROA spectroscopy are sensitive enough to not only detect 
transitions from a disordered to an α-helical or a β-sheet rich ensemble, but also to differentiate 
between the α-helical forms of wild-type (WT) and C-terminal truncated α-syn 107. Using increasing 
concentrations of fluorinated alcohols we induce the aggregation pathway of α-syn and identify a 
molten globule intermediate structure and β-sheet rich oligomers. Taken together, these results 
demonstrate the power of Raman and ROA spectroscopies for the structural elucidation of proteins 
that are challenging to characterise.  
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Introduction 
α-synuclein (α-syn) is a protein that is abundantly expressed in the brain, where it is mainly located in 
the presynaptic terminals and the nucleus.[1,2] Although its physiological function remains unknown, 
α-syn has been suggested to be involved in the regulation of presynaptic vesicles, neurotransmitter 
release, synaptic function and neuronal plasticity.[3–8] It plays a central role in the pathogenesis of 
Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). 
These neurodegenerative diseases are often referred to as (α-)synucleinopathies, since intracellular 
proteinaceous inclusions mainly consist of fibrillar aggregates of α-syn.[9–11] This was reported for the 
first time in 1997 when Spillantini et al. showed that Lewy Bodies and Lewy neurites, the pathological 
hallmarks of PD and DLB, contain α-syn.[11] Missense mutations (A53T, A53E, A30P, E46K, G51D, 
H50Q) and gene duplications or triplications of SNCA, the gene that encodes for α-syn, are linked to 
familial PD.[12–19] Furthermore, sequence variation in SNCA has been identified by genome-wide 
associations studies to be an important risk factor for idiopathic PD.[20] After Alzheimer’s disease, DLB 
is considered the second most common neurodegenerative disease, which explains the vast amount 
of research that focusses on α-syn to elucidate both its native and pathologic properties.[21] 
Nevertheless, the precise mechanism and pathologic properties of this protein are still unknown.[22] 
A key aspect of elucidating the etiology of PD and related neuropathies, is the characterisation of the 
structural propensities of α-syn. Such structural insight can provide insight in the disease progression 
and could aid in the development of therapeutics.[22,23] Although the native structure of α-syn has 
been the matter of debate in scientific literature, a recent study using in-cell nuclear magnetic 
resonance (NMR) and electronic paramagnetic resonance (EPR) showed α-syn to be a monomeric 
and intrinsically disordered protein (IDP) in mammalian cells.[24] While this native structure is very 
dynamic, α-syn adopts a predominantly α-helical structure upon interaction with lipid membranes 
and detergent micelles (see Figure 1).[25] Both this membrane bound α-helical form as well as partial α-
helical structure have been proposed to play a role in the pathologic process and aggregation of α-
syn.[26,27] Nevertheless, the fibrillary aggregates, the pathological hallmarks of DLB, contain a high 
content of β-sheet structure.[28] Because of its ability to adopt different structures and conformations 
depending on the environment, α-syn has been called a chameleon protein.[29] Depending on the 
environment, α-syn has been observed in α-helical, β-sheet, partially folded and disordered 
conformations, besides appearing in monomeric, oligomeric and aggregated forms.[30] 
In this study, Raman optical activity (ROA) is employed to characterise the different conformational 
propensities of α-syn as this spectroscopic technique is exceptionally sensitive to protein secondary 
structure in solution, giving spectral patterns not only specific to each type of secondary structure, 
but sensitive to small alterations and fine-structure details of the conformation.[31–33] This case study 
serves to demonstrate the power of Raman and ROA to study proteins that are challenging to 
characterise, such as α-syn. Structural biology is a multidisciplinary field combining both 
experimental and computational techniques and ROA might provide complementary structural 
information due to its unique sensitivity to the secondary structure of proteins. 
Here, we report the Raman and ROA spectroscopic characteristics of solution phase α-syn adopting 
disordered (IDP), α-helical, partially folded and β-structure conformations. The different 
conformational states of α-syn have been studied and reported in scientific literature based on 
multiple techniques such as NMR, small-angle X-ray scattering (SAXS) and circular dichroism (CD) and 
α-syn is thus an ideal protein to explore the structural sensitivity of ROA in this case study. In 
aqueous solutions, α-syn is an IDP, which was for example demonstrated previously by Syme et al. 
using ROA.[34] In the presence of negatively charged lipids, the N-terminal region (Asp2-Thr92) folds 
into an amphipathic α-helix through the KTKEGV consensus sequence, similar to apolipoproteins.[8,35] 
Inspired by the NMR study by Ulmer et al., the α-helical structure of α-syn interacting with sodium 
dodecyl sulphate (SDS) micelles used as membrane mimics, is studied here for the first time based on 
ROA.[36] Since recent work by our group demonstrated that ROA is very sensitive to subtle changes in 
α-helical conformations,[33] also the structure of the A30P mutant of α-syn (α-syn A30P) in the 
presence of SDS micelles was studied using ROA. This missense mutation replaces an alanine by a 
proline and disrupts a minor part of the α-helical structure α-syn adopts on the micelle surface (see 
Figure 1).[37] The acidic and proline-rich C-terminal region of α-syn remains disordered in these α-
helical structures of α-syn. For that reason, also the Raman and ROA spectra of a C-terminally 
truncated variant of α-syn are reported here to evaluate the sensitivity of ROA to both α-helical and 
disordered structure. Although α-helical intermediates have been reported to be involved in the 
aggregation pathway of α-syn, the fibrillary aggregates of α-syn predominantly contain β-sheet 
structure.[28] The central portion of the α-syn sequence (Glu61-Val95, called the non-amyloid 
component or NAC domain[38]) has a high propensity for β-sheet structure and was shown to drive 
amyloid formation.[39,40] Since ROA is commonly measured from isotropic solutions it is not feasible 
to obtain the ROA spectra of fibrillated forms of α-syn. However, small (fluorinated) alcohols such as 
2,2,2-trifluoroethanol (TFE) have been reported in scientific literature to induce β-structure alongside 
other structures of α-syn, depending on the concentration of TFE.[41,42] At low concentrations of TFE 
(< 10 % v/v) partially folded intermediates are observed, at intermediate concentrations of TFE (10-
35 % v/v), α-syn aggregation is induced, while at high concentration of TFE (> 35 % v/v) α-helical 
structure is detected.[41,42] Although at higher concentration of TFE ROA measurements were not 
feasible due to a high turbidity of the solution possibly because of aggregation of α -syn, the Raman 
and ROA patterns of α-syn in 5 % and 10 % v/v TFE are reported and discussed here. The spectral 
characteristics and differences among the various conformations of α-syn are discussed in detail as 
this study of α-syn is a valuable example of the potential of ROA for structural biology. 
 Figure 1 Sequence and structure of α-syn: (a) Sequence of full length α-syn (residues 1-140) with indication of the three 
domains (N-terminus 1-60, non-amyloid beta component (NAC; 61-95) and C-terminus 96-140), missense mutations (A53T, 
A53E, A30P, E46K, G51D, H50Q), the KTKEGV motive and the residues that adopt α-helical secondary structure upon 
interaction with SDS micelles (residues 2-92). (b) Two conformers of the NMR-based ensemble of intrinsically disordered α-
syn reported by Schwalbe et al.
[43]
 (c) Representation of the cross-β sheet structure adapted from Tuttle et al.
[44]
 (d) WT α-
syn adopting an α-helical structure upon interaction with SDS micelles (PDB id. 1XQ8)
[36]
 compared to (e) the average 
secondary structure of the A30P variant of α-syn without displaying the disordered C-terminus, adapted from Ulmer and 
Bax.
[37]
 VMD version 1.9.2 was used to represent the α-syn structures as cartoons in (b) and (d). In (d) and (e) a partial SDS 
micelle is represented in grey, merely for illustrative purposes. 
Materials and Methods 
Chemicals 
All chemicals were purchased at Sigma-Aldrich with purities > 99.0 % unless stated otherwise.  
Expression and purification of human α-syn (WT, α-syn 107) 
Recombinant wild-type (WT) and truncated (1-107) human α-syn protein were produced in E.coli 
BL21(DE3) cells using the pT7-7 expression system and purified with minor modifications as 
described elsewhere.[45] For the truncated form, a stop codon was inserted after bp 321 of the cDNA 
of human WT α-syn via site-directed mutagenesis (QuickChangeII, Agilent). Summarized, the cells 
were harvested 5 hours after IPTG (1 mM; Thermo Scientific, Erembodegem, Belgium ) induction, 
resuspended in 10 mM Tris-HCl pH 8, 1 mM EDTA supplemented with complete Protease inhibitor 
cocktail (Roche Diagnostics, Vilvoorde, Belgium), heat denatured (6°C 45 min), and lysed by 
sonication followed by centrifugation (10.000 x g 20 min at 4°C). A serially executed streptomycin 
sulphate precipitation (1% m/v centrifuged at 13.500 x g for 30 min at 4 °C) and ammonium sulphate 
precipitation (30% m/v centrifuged at 13.500 x g for 30 min at 4 °C) were carried out on the clarified 
supernatant. The resultant semi-pure WT α-syn 107 pellets were resuspended in 10 mM Tris-HCl pH 
7.4 or pH 8 resp. and loaded on HiPrep 16/60 Sephacryl S-100 HR column (GE Healthcare, Machelen 
Belgium) using an Åkta chromatography system (GE Healthcare). Next, WT α -syn fractions were 
pooled and anion exchanged (HiLoad 16/10 Q sepharose HP column, GE Healthcare), while α-syn 107 
was purified by sequential anion exchange (1 ml HiTrap Q, GE Healthcare) and cation exchange (1 ml 
HiTrap SP, GE Healthcare). In both cases fractions of highly pure α-syn were collected upon 
generation of linear gradient towards buffer B (10 mM Tris-HCl pH 7.4 and pH 8 resp, 0.5 M NaCl). α-
syn containing fractions were pooled and dialyzed against 50 mM ammonium bicarbonate, 
lyophilized and stored until use at -80°C. The purity and concentration of the proteins was 
determined using SDS-PAGE and a Pierce BCA protein assay. Lyophilized α-syn A30P was kindly 
donated by prof. R. Grandori (University of Milano-Bicocca) and used without further purification.  
Sample preparation for Raman and ROA spectroscopy 
Protein solutions for Raman and ROA spectroscopy were prepared by dissolving the lyophilised 
protein (WT α-syn, α-syn 107, α-syn A30P) in deionised water, aqueous SDS solution (Amersham 
Biosciences, 99.0%, Uppsala, Sweden; stock solution with a concentration of SDS of 328 mM) or TFE 
(5% or 10% v/v in deionised water) to a final concentration of 30-50 mg/mL of protein. The resulting 
solution was directly loaded in a quartz cuvette and used for Raman and ROA collection. 
Raman and ROA spectroscopy 
The Raman and ROA spectra were measured at ambient conditions using the previously described 
ChiralRAMAN-2X scattered circular polarization (SCP) ROA instrument (BioTools, Inc).[46,47] The Raman 
spectra are displayed as the circular intensity sums (IR + IL) and the ROA spectra as the circular 
intensity differences (IR – IL) with IR and IL denoting the scattered Raman intensities with right- and 
left-circular polarization, respectively. The instrument excitation wavelength was 532 nm; laser 
power at the source was in the range of 400-800 mW, depending on the sample; spectral resolution 
of 7 cm-1; and illumination times of 24-40 hours. Solvent spectra were subtracted from the Raman 
spectra after which the baseline correction procedure by Boelens et al. was applied, unless stated 
otherwise.[48] The ROA spectra were smoothed using a 3rd order, 5-point Savitzky-Golay filter, except 
when specified otherwise. 
Results and Discussion 
intrinsically disordered α-synuclein. 
The Raman and ROA spectrum of α-syn in aqueous solution show distinct patterns for a protein that 
is structurally disordered (Figure 2).[34] In the Raman spectrum, the amide I region (1630-1700 cm-1) is 
the most distinctive spectral region to study secondary structure, as it arises mainly from the 
carbonyl stretch in the polyamide backbone of the protein. The broad band with a maximum at 1674 
cm-1 is assigned to disordered structure similar to an earlier report on the Raman characteristics of α-
syn in aqueous buffer solution.[49] Although many Raman bands arise from the side-chains of the 
protein, the extended amide III region (1230-1340 cm-1) is also very sensitive to secondary structure, 
since it involves in-phase combination of N-H in-plane deformation with C-N stretching.[50] The 
coupling of N-H and Cα-H deformations in these vibrational modes is very sensitive to the exact 
geometry. The broad amide III Raman band around 1254 cm-1 is assigned to disordered or random 
protein conformations. While the secondary structure analysis from Raman spectra is hampered by 
the many contributions from the side-chains, the strength of ROA stems from its sensitivity to 
chirality. The main ROA patterns of proteins arise from the most rigid and chiral structural 
components, which is the peptide backbone conformation; i.e. the secondary structure. Most 
spectral contributions from side-chains cancel out, due to their flexibility and the occurrence of 
multiple of the same residues with different side-chain conformations. As a result, ROA spectral 
patterns mainly occur in the amide I, amide III and skeletal stretch (Cα-C, Cα- Cβ and Cα-N stretch; 
870-1150 cm-1)[31] regions, which makes ROA exceptionally sensitive to secondary structure. 
However, side-chain CH2 and CH3 deformations (1430-1470 cm
-1)[31,50] and a conformationally 
sensitive tryptophan band (~ 1550 cm-1)[51,52] are separately observed in ROA spectra, for example. 
The ROA spectrum of α-syn was published before by Syme et al. at a lower resolution than the one 
shown in Figure 2. Because of the disordered nature, it seems more challenging to obtain a good 
signal-to-noise ratio for IDPs. A broad ROA amide I band with a maximum at 1680 cm-1 is observed, 
which is assigned to disordered or polyproline II (PPII; backbone torsion angles φ; Ψ of -75°; 145°) 
structure.[31,33] Based on spectroscopic methods such as ROA, PPII was identified in the past to be an 
important local conformation of IDPs.[53–55] Model peptides such as the XAO peptide (Ac-XXA7OO-
NH2) were shown by a multitude of techniques to adopt a flexible structure with torsion angles 
fluctuating in the PPII region of the Ramachandran plot.[33,54,56] Such structures do not support regular 
patterns of intramolecular hydrogen bonding. Furthermore, in the amide III region of the ROA 
spectrum, α-syn shows a maximum at 1324 cm-1 which is indicative for this kind of PPII structure 
implicated in IDPs. This observation confirms that α-syn has many torsion angles found in the PPII 
region of the Ramachandran plot (fluctuating around -75°;145°). The broadness of the 1324 cm-1 
band likely stems from structural heterogeneity and solvation of the structure. A -/+ couplet in the 
skeletal stretch region, negative at 1093 cm-1 and positive at 1129 cm-1 is observed both for α-helical 
proteins and IDPs.[33,34] For α-syn, it suggests local residual structure of the backbone, hence either α-
helical or PPII-like. Besides the latter couplet, the skeletal stretch region does not show spectral 
patterns, indicating a flexible and disordered structure. These observations are consistent with 
structural studies using NMR, which show that in vitro α-syn adopts a disordered structure with a 
large proportion of the backbone torsion angles fluctuating around the ideal angles for PPII 
structure.[43,57] Also in mammalian cells, α-syn was primarily found as a disordered monomer, 
however adopting more compact conformations, compared to buffered solution.[24] 
 
Figure 2 Raman (left; IR+IL) and ROA (right; IR-IL) of 40 mg/mL human WT α-syn in aqueous solution. The ROA spectrum was 
baselined by overly smoothing the ROA spectrum using a Savitzky-Golay filter. 
α-helical α-synuclein  
When α-syn is presented with a membrane mimicking environment, such as SDS micelles, a drastic 
change to the Raman and specifically the ROA spectrum is observed (Figure 3). Compared to the 
Raman spectrum of disordered α-syn in aqueous solution (Figure 2), a redshift of the amide I band to 
1654 cm-1 is observed, characteristic of α-helical structure. The intensity of the Raman band observed 
in disordered α-syn at 1254 cm-1 is significantly lower in the SDS solution. The structural difference 
between disordered α-syn in aqueous solution and α-helical α-syn in SDS solution is distinctly clear in 
the different ROA spectra. All spectral patterns have changed: The amide I couplet negative at 1627 
cm-1 and positive at 1667 cm-1, the amide III -/+/+ pattern at 1242/1305/1346 cm-1 with the two 
positive ROA bands characteristic of α-helical structure, a -/+ couplet at 1091/1127 cm-1 and positive 
intensity in the skeletal stretch region at 931 cm-1 are all ROA patterns traditionally assigned to α-
helical structure.[31,33] This is in accordance with several other reports using CD, SAXS, NMR and EPR 
of α-syn interacting with SDS or sodium lauroyl sarcosinate (SLAS).[36,58,59] Upon interaction with SDS 
or SLAS micelles, the N-terminal region of α-syn (residues Asp2-Thr92) adopts an amphipathic α-helix 
on top of the detergent micelles. The C-terminus remains a disordered tail extending flexibly into 
solution, as can be seen in the molecular structures deposited in the protein data bank (PDB id. 
2KKW[59] and 1XQ8[36]). As shown in the NMR study by Ulmer et al., the structure of micelle-bound α-
syn consists of two curved, anti-parallel α-helices (Val3-Val37 and Lys45-Thr92) which are connected 
by an extended linker of seven residues (Leu38-Thr44) with a propensity to form a turn (see Figure 
1).[36] The extended amide III region observed here is very similar to the ROA patterns of several viral 
coat proteins of filamentous bacteriophages (e.g. M13 and fd) that have amphipathic α-helical 
structures as reported by Blanch et al.[60,61] While two positive bands, the first around 1300 cm-1 and 
the second around 1345 cm-1, are observed for α-helical proteins, the intensity ratio of these two 
bands has been the matter of debate in scientific literature.[32,33,60,62] Based on recent work by our 
group , the dominant ROA band around 1345 cm-1 of α-helical α-syn is assigned to regular α-helical 
structure,[33] which is consistent with the NMR structure of micelle-bound α-syn (PDB id. 1XQ8). The 
ROA band observed around 1300 cm-1 was shown in our earlier work to be much more sensitive to 
the conformation of the α-helix than the 1345 cm-1 signature. A very intense band at 1300 cm-1 
indicates either solvent exposure or structural heterogeneity of the helical portions of the protein.[33] 
The amide III pattern observed here is in accordance with the formation of an amphipathic helix 
consisting of long stretches of α-helix with a hydrophobic side and a hydrophilic face exposed to the 
solvent, such as is seen in the NMR structure. 
 
Figure 3 Raman (left; IR+IL) and ROA (right; IR-IL) spectra of α-syn (50 mg/mL) in a high concentration of SDS (328 mM; 40 
times the CMC in water): (a) the α-syn A30P variant; (b) α-syn 107 and (c) WT α-syn. For each Raman spectrum, the Raman 
spectrum of the SDS solution was firstly subtracted after which the baseline correction by Boelens et al. was applied.
[48]
 The 
Raman spectrum of the aqueous SDS solution is given as a dotted line in the panel of the Raman spectrum of WT α-syn. 
Interestingly, while α-syn does not contain a tryptophan residue, which has a distinct band around 
1555 cm-1, both the Raman and ROA spectrum of α-syn in SDS solution show a small contribution in 
the amide II region, clearly identifiable, as SDS also does not have a Raman band in that region. 
Amide II vibrations arise from out-of-phase N-H in-plane deformations with C-N stretching and are 
not often distinctly observed in ROA spectra. McColl et al. suggested that a positive amide II band 
might be assigned to β-sheet structure and that unusually large positive amide II bands are a 
characteristic of flat β-sheet.[63] The ROA spectra of α-helical α-syn however show that such a positive 
band can also be observed for α-helical structure. It is possible that the local environment of the 
amides is affected by the interaction of the amphipathic helical structure with the SDS micelles, 
giving rise to the observed amide II band. 
The ROA spectrum of WT α-syn bound to SDS micelles does not contain a significant contribution 
from the disordered tail. The most prominent amide III band at 1324 cm-1 observed in the spectrum 
of disordered α-syn is not visible in the amide III region of α-helical α-syn. The amide I is a -/+ couplet 
characteristic for α-helical structure. To investigate whether the disordered tail affects the α-helical 
N-terminus, and furthermore if a spectral pattern can be deducted for the disordered C-terminus, 
the ROA spectrum of C-terminally truncated α-syn 107 was recorded. This α-syn form lacks 33 
residues from the disordered tail, while the sequence making up the amphipathic α-helix is retained. 
As can be seen in Figure 3, the spectrum of α-helical WT α-syn is very similar to that of the truncated 
variant. However, it seems small differences in the ROA spectra can be carefully deduced. The amide 
I region in the ROA spectra of the WT and α-syn 107 is the same, while the amide III region shows 
minor differences. This demonstrates that the amide III region is the most sensitive to the three-
dimensional structure of proteins in solution. Principally, by subtracting the ROA spectrum of α-syn 
107 from the WT α-syn spectrum, only the spectrum of the disordered tail is retained, assuming the 
structure of the α-helical part is unaltered. Since this involves only 33 out of 140 residues, the 
difference as displayed in Figure 4 is noisy. Nevertheless, the difference ROA band at 1326 cm-1 
indicates a higher content of disordered structure in WT α-syn than in C-terminally truncated α-syn 
107. The negative features at 1300 cm-1 and 1346 cm-1 suggest that α-syn 107 adopts a slightly higher 
α-helical content. However, at this signal-to-noise ratio, care must be exerted not to overly interpret 
the data. By taking the difference of the Raman spectra, the most prominent positive amide bands 
are observed at 1251 cm-1 (amide III) and 1679 cm-1 (amide I), reinforcing the conclusion from the 
ROA spectra that WT α-syn displays a more disordered structure upon interacting with SDS micelles, 
since its C-terminus is disordered. The positive band at 1618 cm-1 in the Raman difference is observed 
as five out of five phenylalanine residues and three out of four tyrosine residues occur in the C-
terminal sequence, which is not present in the truncated α-syn 107 variant. The small negative 
contribution at 1652 cm-1 also suggests α-syn 107 adopts a slightly higher α-helical content. The 
spectral differences in the regions 1000-1140 cm-1 and 1430-1460 cm-1 are difficult to interpret as the 
corresponding vibrational modes comprise CH2 and CH3 deformations both of the protein and SDS 
(1064 cm-1 and 1459 cm-1).  
 Figure 4 Raman (left; IR+IL) and ROA (right; IR-IL) spectral differences of WT α-syn (black solid line) and α-syn 107 (red solid 
line): The top panels present the aligned spectra with their respective difference (α-syn 107 subtracted from WT α-syn) 
shown in the bottom panels. The square root of the WT α-syn Raman spectrum multiplied by 2 and -2 is plotted as the 
dashed red lines in the bottom right panel. These lines represent an estimation of the shot noise level (multiplied by 2 due to 
the difference of 2 spectra). The Raman spectra were firstly baselined before the subtraction.
[48]
 The Raman spectrum of the 
SDS solution was not subtracted, but it is shown on top of the Raman difference spectrum as a red dashed line to represent 
regions where SDS has intense Raman bands. The ROA spectra of WT α-syn and α-syn 107 and the difference are the raw 
measured data without smoothing or baseline correction.  
A number of hereditary missense mutations have been identified that are related to the aggregation 
propensity of α-syn and developing of early onset of synucleinopathies. Although some mutations 
(eg. A53T) do not directly influence the ensemble structure of α-syn monomers interacting with 
micelles, the A30P mutation , which due to the introduction of a proline residue interrupts one helix 
turn (Val26-Ala29), causes the N-terminal α-helix to terminate at Ala27 instead of Val37.[37] The A30P 
mutation has been shown to disrupt the equilibrium between the membrane bound and cytosolic α-
syn species and might explain the early onset of synucleinopathies observed for patients with this 
missense mutation.[64,65] The NMR study by Ulmer and Bax revealed that the backbone order changes 
for approximately 10 residues in the micelle-bound A30P mutant compared to WT α-syn, while the 
remainder of the structure essentially remains unaffected. [37] The ROA spectrum of the A30P mutant 
of α-syn shows a very similar pattern compared to the WT. The effect of a change in the short stretch 
of α-helix that changes to an extended disordered conformation is not evidently visible in the 
spectrum. This is in accordance with the results discussed above, that mainly the most chiral parts of 
the protein are picked up by ROA. Furthermore, a change in secondary structure in 10 amino acids (7 
% of the protein) is a subtle change compare to a truncation of 33 residues (24 % of the protein).  
Although disordered structure has a characteristic ROA pattern, the spectrum here is dominated by 
signals arising from the predominantly α-helical structure that is stable. Even so, the ROA spectrum 
of A30P in the presence of SDS micelles does appear to contain slight differences from WT α-syn, 
which ideally should be studied in more detail. Unfortunately, it was not possible to produce a 
difference spectrum of sufficient quality to detect the minor spectral differences that could be 
expected with the small change in secondary structure caused by the A30P mutation (see Figure S.1). 
Based on the strong sensitivity of the ROA band around 1307 cm-1 to small conformational changes, a 
larger change of the band intensity would be expected concomitant with a change in the helicity or 
flexibility.[33] This is in accordance with the NMR study by Ulmer and Bax that showed that the 
backbone order only changed significantly for the residues Gln24–Lys32; the N-terminal α-helix did 
not reveal a significant change.[37] The only significant spectral change in the difference ROA 
spectrum shown in Figure S.1, is a negative ROA band with a minimum at 1446 cm-1, which is present 
in the ROA spectrum of WT α-syn and not in that of the A30P variant.  This spectral difference likely 
supports the slightly different interaction of the protein with the micelle and concomitant effect on 
the micelle shape reported by Ulmer and Bax.[37] The spectral region around 1446 cm-1 arises from 
CH2 and CH3 deformations, hence a change in the interaction of the protein with SDS micelles could 
alter the spectral contribution from the aliphatic chains of the detergent. Nevertheless, the small 
structural changes induced by the A30P mutation are apparently enough to induce defective 
membrane binding for the A30P mutant. 
α-synuclein forms a partially folded state and oligomerizes in low concentrations of TFE. 
Considering the involvement of α-syn in PD and related neurodegenerative diseases, one of the most 
studied aspect of this protein is its aggregation properties.[27,41,42,58,66,67] The use of small, fluorinated 
alcohols has been proposed in the past to model the effect of phospholipid vesicles on α-syn.[41,42] 
Although 2,2,2-trifluoroethanol (TFE) is often used in structural biology to induce α-helical structure, 
when α-syn is incubated in intermediate concentrations of TFE (10-20 % v/v) it forms β-sheet-rich 
fibrillary species.[41,42] At concentrations above 40 % v/v of TFE, highly α-helical α-syn is observed. 
Unfortunately, at such high concentration of TFE, we were not able to record ROA because of too low 
solubility and hence high turbidity of the sample because of the high protein concentration required 
for ROA measurements. Nonetheless, the Raman and ROA spectra of α-syn in aqueous solution with 
5 % v/v or 10 % v/v TFE were recorded and are depicted in Figure 5. The amide I region of both Raman 
spectra displays a maximum at 1669-1671 cm-1, which together with the amide III band around 1241-
1246 cm-1 indicates β-sheet structure both at 5 % and 10 % v/v TFE, mixed with disordered structure. 
Compared to the ROA spectra of α-syn in its IDP and α-helical states, the ROA spectra in TFE solution 
are distinctly different, again illustrating the secondary structure sensitivity of ROA. Different ROA 
spectra for proteins containing diverse forms of β-sheet have been reported, however, as reviewed 
by Weymuth and Reiher, only a few signatures can be regarded as reliable β-sheet characteristics 
while many other β-sheet and turn signatures have been suggested.[68] They propose that only a -/+ 
couplet centred around 1650-1670 cm-1 and negative intensity in the region 1240-1255 cm-1 are 
reliable markers of β-sheet structure. Yet, positive intensity in the extended amide III region 1260-
1330 cm-1, flanked by negative intensity on both sides 1240-1255 cm-1 and 1240-1280 cm-1 is 
consistently observed for proteins containing mainly β-sheet structure.[31,63] Overlap or proximity of 
characteristic regions of different secondary structure types together with the large diversity of β-
structure impedes the detailed assignment of marker bands of β-sheet, which complicates a detailed 
analysis of the ROA patterns observed here. In the spectrum of α-syn in 10 % TFE, the -/+ couplet, 
negative at 1662 cm-1 and positive at 1678 cm-1 is indicative of β-sheet. However, in 5 % TFE the 
negative contribution of the amide I couplet is not present. This observation suggests that in 10 % 
TFE the content of β-sheet is higher, while in 5 % TFE there are contributions of a mixture of 
secondary structure elements. The latter sample remained stable for multiple days during ROA 
acquisition, while in 10 % TFE the aggregation of α-syn complicated the ROA measurement due to 
increased light scattering from particulates in the sample, which explains the lower signal-to-noise 
that could be obtained from this sample. Similar narrow amide I ROA bands such as the one at 1678 
cm-1 in the 5 % TFE measurement were previously reported for the Bowman-Birk protease 
inhibitor[55], the A-state of α-lactalbumin[69] and the intermediate states in the renaturing of insulin 
from its amyloid state[70]. In these reports this band was assigned to a disordered type of 
conformation with PPII contribution. It should however be noted that in the ROA spectra of proteins 
and peptides with a disordered/PPII type of structural propensity, the amide I is considerably 
broader, arising from a flexible structure surrounded by water. In this case, α-syn in 5 % TFE adopts a 
more compact structure compared to its intrinsically disordered structure in water. Interestingly, the 
positive band at 1564 cm-1 can be assigned to amide II vibrations since α-syn has no tryptophan 
residue in its sequence, similar to the assignment of this spectral band of poly-L-lysine in a mainly β-
sheet state.[63] The negative band observed at 1617 cm-1 in the spectra of α-syn in both 5 % and 10 % 
TFE and more generally the +/-/+/-/+ pattern at 1564/1617/1637/1662/1678 cm-1 in 10 % TFE is 
reminiscent of this spectral region in the ROA spectra of reduced hen lysozyme,[31] reduced bovine 
ribonuclease A,[31] reduced prion (PrP94-223),[63] the molten globule A-state of bovine α-lactalbumin[69] 
and the renaturing intermediate of insulin amyloid[70], which are all dynamic states of these proteins 
that populate different secondary structure elements. Also a few β-sheet proteins display a similar 
pattern in the 1540-1700 cm-1 region such as P.69 pertactin,[63] of which the crystal structure 
resembles models of amyloid structure due to its parallel β-sheet arrangement,[71] and poly-L-lysine 
in a β-sheet state.[63] The latter observations might suggest that such a ROA pattern arises from the 
formation of β-sheet structure, indicating that oligomeric species are present, which was for example 
also suggested before for reduced hen lysozyme.[31] This also implicates that α-syn in 10 % TFE forms 
oligomers, which is reasonable considering the high concentration of α-syn (30 mg/mL) in this 
sample. In 5 % TFE, the lack of the positive band at 1037 cm-1, no negative intensity around 1340-
1380 cm-1 and no negative band at 1662 cm-1 indicate a more dynamic structure with the population 
of different secondary structures. These assignments of the ROA patterns are however tentative as 
the 1540-1700 cm-1 comprises the amide II, amide I and aromatic residues (tyrosine and 
phenylalanine ~ 1600-1625 cm-1; tryptophan ~ 1555 cm-1)[50], which might couple to the amide 
vibrations. The 1561 cm-1 band in the ROA spectrum of poly-L-lysine (which lacks aromatic residues), 
for example, was however assigned to amide II vibrations, since hydrogen/deuterium exchange 
resulted in a large shift of this band, demonstrating the involvement of N-H protons (the amide II 
vibration is an in-phase combination of NH in-plane deformation and CN stretching).[63] To conclude 
the discussion above, ROA indicates that in 5 % TFE α-syn adopts a partially folded structure. Such a 
state of α-syn has been referred to as a pre-moIten globule by Uversky,[30] which is consistent with 
the high similarity of the ROA spectrum of α-syn in 5 % TFE with that of e.g. the molten globule A-
state of α-lactalbumin.[69] In 10 % TFE, α-syn (here at 30 mg/mL) aggregates with the formation of β-
sheet rich structures. The ROA spectrum of α-syn in 10 % TFE is very similar to that of reduced ovine 
PrP94-233, which was suggested by McColl et al. to be characteristic of unusually flat and regular β-
sheet structure.[63] Both in 5 % and 10 % TFE, α-syn is known to aggregate upon agitation (shaking at 
37°C) for a prolonged time.[42] Previously, Anderson et al. reported that in 5 % TFE amyloid fibrils 
were formed, while in 10 % TFE classic amyloid fibrils were not observed but flexible, short “TFE 
fibrils” were formed.[42] Probably, the ROA spectrum in 5 % represents an intermediate state in the 
TFE aggregation pathway. 
 
 
Figure 5 Raman (left; IR+IL) and ROA (right; IR-IL) spectra of 30 mg/mL α-syn in 5 % (top) and 10 % v/v (bottom) TFE in 
demineralised water. The baselined
[48]
 Raman spectrum of the corresponding TFE solutions are given in dashed lines in 
comparison to the Raman spectra of α-syn (solid line) to illustrate which spectral regions (e.g. around 832 cm
-1
 in Raman 
and ROA) are sensitive to solvent artefacts. Due to scattering from larger particles indicating aggregation of α-syn in 10 % 
TFE, a lower resolution was obtained in ROA for the corresponding ROA spectrum. Furthermore, because of the higher 
stability of the 5 % TFE sample, the sample was monitored with Raman and ROA for one week, but did not change over time. 
Conclusions 
Although the protein α-synuclein (α-syn) plays a central role in Parkinson’s disease, both its precise 
involvement in the pathology as well as its native function are poorly understood. α-syn is 
challenging to characterise since its structure is very sensitive to its environment; it is capable of 
adopting disordered, helical, β-sheet and partially folded structures. As this structural behaviour has 
received much attention in scientific literature, α-syn provided an ideal case study to assess and 
demonstrate the secondary structure sensitivity of Raman and ROA to characterise the different 
conformations of α-syn. In the present study, we show that all the main forms of secondary structure 
elements, e.g. disordered, helical and β-sheet, dominate α-syn under different conditions and can be 
studied by ROA. In aqueous solution, α-syn is an intrinsically disordered protein, as shown by the 
Raman and ROA spectra. In the presence of SDS micelles, α-syn adopts a stable α-helical structure. 
Comparison of the Raman and ROA spectra of WT α-syn with the C-terminally truncated (at residue 
107) variant reveals that the C-terminal of the WT variant remains disordered upon interaction with 
detergent micelles, consistent with reports in literature based on CD and NMR techniques. The 
truncated variant α-syn 107 seems to have a slightly higher α-helical structure. The A30P mutant of 
α-syn adopts an α-helical structure upon interaction with detergent micelles comparable to the WT. 
Although a short stretch of α-helix is lost due to the mutation, the ROA spectra of the A30P mutant 
and WT α-syn did not reveal a significant difference, thus demonstrating the limit of ROA in detecting 
structural differences. The α-helical conformation is not significantly altered due to the A30P 
mutation, nor has its hydration significantly increased. In 5 % v/v TFE, α-syn adopts a pre-molten 
globule or partially folded structure, which probably is an intermediate in the formation of 
aggregates. The ROA spectrum is very similar to that of α-syn in 10 % TFE. However, in 10 % TFE a 
few bands clearly show a higher content of β-structure, indicating oligomerization and aggregation of 
α-syn. The results are in accordance with earlier reports on the various structures of α-syn based on, 
for example, NMR and CD and hence demonstrate the use of Raman and ROA to characterise 
proteins that are of interest in structural biology, both as complementary and stand-alone tools. 
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